Sciele to acquire Addrenex for $29 million

Sciele Pharma will pay $29 million in cash for Addrenex Pharmaceuticals, in a transaction which builds on a series of product licensing deals between the two US firms over the past few years.

Sciele Pharma will pay $29 million in cash for Addrenex Pharmaceuticals, in a transaction which builds on a series of product licensing deals between the two US firms over the past few years.

The immediate benefits for Sciele, itself acquired by Shionogi for $1.4 billion just over a year ago, include access to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category